UCB SA (OTCMKTS:UCBJY) Sees Significant Drop in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 700 shares, a decline of 90.0% from the February 29th total of 7,000 shares. Based on an average daily trading volume, of 14,300 shares, the days-to-cover ratio is currently 0.0 days.

UCB Trading Down 0.5 %

OTCMKTS:UCBJY traded down $0.30 during midday trading on Wednesday, reaching $61.57. 6,213 shares of the stock traded hands, compared to its average volume of 11,682. The company has a fifty day moving average of $52.79 and a 200 day moving average of $44.95. UCB has a 12 month low of $34.85 and a 12 month high of $62.53.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.